FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

Journal of Neuroscience Research

Volumn 88, Issue 2, 2010, Pages 346-359

  Papadopoulos, Dimitrios ^a   Rundle, Jon ^a   Patel, Ryan ^a   Marshall, Ian ^b   Stretton, Jennifer ^b   Eaton, Rachel ^b   Richardson, Jill C ^b   Gonzalez, Maria I ^b   Philpott, Karen L ^b   Reynolds, Richard ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Axon loss; Demyelination; EAE; FTY720; Immunosuppression; MOG; Multiple sclerosis; Neurodegeneration; Sphingosine 1 phosphate receptors

Indexed keywords

AUTOANTIBODY; CYTOKINE; FINGOLIMOD; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PLACEBO; PROTEIN ANTIBODY; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLOOD; CELLULAR IMMUNITY; CONTROLLED STUDY; DARK AGOUTI RAT; DEMYELINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPH NODE; NERVE DEGENERATION; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SPINAL CORD; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; AUTOANTIBODIES; AXONS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; PROPYLENE GLYCOLS; RATS; RATS, INBRED STRAINS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; SPINAL CORD; TIME FACTORS;

EID: 74049160871     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22196     Document Type: Article

References (60)

1. Allende ML, Dreier JL, Mandala S, Proia RL. 2004. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279:15396-15401.
2. Antel J, Bar-Or A. 2006. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 180:3-8.
3. Balatoni B, Storch MK, Swoboda E-M, Schonborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA. 2007. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74:307-316.
4. Bechtold DA, Kapoor R, Smith KJ. 2004. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607-616.
5. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck WA. 2000. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174-1183.
6. Blesch A, Tuszynski MH. 2003. Cellular GDNF delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transections and includes remyelination. J Comp Neurol 467:403-417.
7. Brinkmann V. 2007. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115:84-105.
8. Brinkmann V, Baumruker T. 2006. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 6:244-250.
9. Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y. 1998. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160:5037-5044.
10. Chiba K, Matsuyuki H, Maeda Y, Sugahara K. 2006. Role of sphingosine 1-phosphate receptor 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 3:11-19.
11. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. 2007. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323:626-635.
12. Compston DAS, Coles A. 2002. Multiple sclerosis. Lancet 359:1221-1231.
13. + regulatory T cells. J Immunol 178:2458-2468.
14. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A. 2008. Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117:77-93.
15. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
16. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A. 2007. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in te CNS during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469-476.
17. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T. 2009. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 19:254-266.
18. Han S, Zhang X, Wang G, Guan H, Garcia G, Li P, Feng L, Zheng B. 2004. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 104:4129-4133.
19. Hofmann M, Brinkmann V, Zerwes HG. 2006. FTY720 preferentially depletes naïve T cells from peripheral and lymphoid organs. Int Immunopharmacol 6:1902-1910.
20. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. 2001. Tand B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220-234.
21. Iwase T, Jung CG, Bae H, Zhang M, Soliven B. 2005. Glial cell linederived neurotrophic factor- induced signalling in Schwann cells. J Neurochem 94:1488-1499.
22. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, Walsh FS, Pangalos MN, Arimura N, Kaibuchi K, Zalc B, Lubetzki C. 2005. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25:1459-1469.
23. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, Ántel JP, Soliven B. 2007. Functional consequences of S1P receptor modulation in rat oligodendoglial lineage cells. Glia 55:1656-1667.
24. Kappos L, Antel J, Comi G, Montalban X, O Connor P, Polman C, Haas T, Korn A, Karlsson G, Radue EW. 2006. Oral fingolimod (FTY720) for Relapsing Multiple Sclerosis. N Engl J Med 355:1124-1140.
25. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K. 2005. FTY720 sphingosine 1-phosphate receptor modulator ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2:439-448.
26. Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, Murakami T, Kobayashi E, Hoshino Y, Yatomi Y, Sakata Y. 2007. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25:115-124.
27. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13:423-431.
28. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
29. Liao J-J, Huang M-C, Goetzl EJ. 2007. Cutting edge: alternative signalling of Th17 cell development by sphingosine 1-phosphate. J Immunol 178:5425-5428.
30. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
31. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508.
32. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. 2002. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 296:346-349.
33. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 201:291-301.
34. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101-104.
35. McFarland HF, Martin R. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919.
36. Medana I, Martinic MA, Wekerle H, Neumann H. 2001. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 159:809-815.
37. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RLP, Kappos L. 2008. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurol 71:1261-1267.
38. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. 2008a. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63:61-71.
39. Miron VE, Schubart A, Antel JP. 2008b. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274:13-17.
40. Muraro PA, Bielekova B. 2007. Emerging therapies for multiple sclerosis. Neurotherapeutics 4:676-692.
41. Newman TA, Wooley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. 2001. T-cell and macrophage mediated axon damage in the absence of a CNS specific immune response: involvement of metalloproteinases. Brain 124:2203-2214.
42. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. 2007. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 21:1503-1514.
43. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY, Hla T. 2007. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082-9089.
44. Osinde M, Mullershausen F, Dev KK. 2007. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52:1210-1218.
45. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. 2003. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase 2. FEBS Lett 554:189-193.
46. Papadopoulos D, Pham-Dinh D, Reynolds R. 2006. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol 197:373-385.
47. Peñuelas-Rivas G, Dominguez-Perles R, Brinkmann V, del Rio ML, Muñoz-Luna A, Ramirez-Romero P, Parrilla-Paricio P, Rodriguez-Barbosa JI. 2005. FTY720 inhibits TH1-mediated allogeneic humoral immune response. Transplant Proc 37:4124-4126.
48. Piddlesden S, Lassmann H, Zimprich F, Morgan BP, Linington C. 1993. The demyelinating potential of antibodies to myelin oligodendroglia glycoprotein is related to their ability to fix complement. Am J Pathol 143:555-564.
49. Reynolds R, Dawson MRL, Papadopoulos D, Polito A, DiBello IC, Pham-Dihn D, Levine J. 2002. The response of NG-2 expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 31:523-536.
50. Rouach N, Pébay A, Même W, Cordier J, Ezan P, Etienne E, Giaume C, Tencé M. 2006. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 23:1453-1464.
51. Sato K, Ishikawa K, Ui M, Okajima F. 1999. Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells. Brain Res Mol Brain Res 74:182-189.
52. Schwab SR, Cyster JG. 2007. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295-1301.
53. Smith KJ, Kapoor R, Felts PA. 2001. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49:470-476.
54. Smith T, Groom A, Zhu B, Turski L. 2000. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62-66.
55. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerchensteiner M, Olsson T, Linington C, Lassmann H. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694.
56. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
57. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous systeminfiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-155.
58. Vaknin-Dembinsky A, Balashov K, Weiner HL. 2006. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176:7768-7774.
59. Webb M, Tham C-S, Lin F-F, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, Rao TS. 2004. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153:108-121.
60. Yamagata K, Tagami M, Torii Y, Takenaga F, Tsumagari S, Itoh S, Yamori Y, Nara Y. 2003. Sphingosine-1 phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 41:199-206.